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Abstract
High-risk human papillomavirus (HPV) types are not only associated to uterine cervical 
cancer, but also to a fraction of cancers of the vulva, vagina, penis, anus, head and neck. 
An HPV infection generates a protective humoral immune response against the capsid 
proteins L1 and L2; however, an immune response against other HPV early proteins is 
also generated. This latter is not a protective response, but those antibodies can be useful 
as biomarkers of the status of the infection and/or the stage of the cancer lesion. Until now, 
there are no conclusive results regarding the use of anti-HPV antibodies as biomarkers 
in diagnosis. In this review, we hereby summarized the actual panorama of the humoral 
immune response against different HPV early proteins during the development of the 
disease as possible biomarkers for the prediction and detection of HPV-associated cancers.
Keywords: serological biomarkers, human papillomavirus, humoral immune response, 
HPV-associated cancers, cancer diagnostic
1. Introduction
Prevention of cervical cancer (CC) and other related human papillomavirus (HPV) diseases 
constitutes a public health priority worldwide [1]. Primary prevention has been achieved 
through the introduction of the prophylactic HPV vaccines, but the target groups are only 
adolescent girls and young women (up to 25 years old) [2]. Secondary prevention has been 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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implemented through screening methods to prevent precancerous lesions from progressing 
to cancer [3]. The CC prevention programs in the world are based on cervical cytology and 
colposcopy to detect precancerous lesions, which have helped to reduce significantly the inci-
dence of this illness in countries with well-organized programs and good coverage of the 
target population, but this is not the case in developing countries [4, 5]. The main problems 
are the lack of qualified personnel, the poor quality of the screening tests, lack of follow-up 
colposcopy and treatment, and over-saturation of the health system facilities, estimating that 
less than 20% of the CC cases are detected opportunely in these countries [6]. The HPV has 
been the target for the new molecular diagnostic technologies to detect high-risk (HR)-HPV 
DNA in cervical cells, but these tests have not been sufficient to discriminate women with 
precancerous lesions in progression to cancer, from those that eliminate the infection and the 
lesion. Thus, the increasing incidence of HPV-related cancers worldwide, the inefficacy of the 
cancer prevention programs in developing countries, and the lack of efficient HPV diagnostic 
tests, make this a priority health problem worldwide [7].
For this reason, it is important to develop new screening methods, which should achieve 
high sensitivity, specificity, and should be inexpensive for developing countries. These new 
diagnostic methods could be used in triage with the cytology or HPV-screening tests to detect 
opportunely women at risk to develop CC. In addition, it would be important to develop new 
technologies and to identify new biomarkers that allow the early detection of other HPV-
related cancers. In this sense, antibodies against HPV antigens have become the new bio-
markers that can be used to detect persistent HPV infection that in combination with other 
molecular tests could be useful for early detection of HPV-associated cancers.
2. Differential expression of human papillomavirus proteins during 
the viral cycle
The HPV is a non-enveloped icosahedral virus of approximately 50 nm in diameter that con-
tains a double-stranded circular DNA genome of around 8 Kb, which is divided into three 
regions: the long control region (LCR) that regulates the viral DNA transcription and rep-
lication; the early region (E1, E2, E4, E5, E6, and E7 genes) that controls the transcription 
and replication of the viral genome as well as to control the carcinogenesis; the late region 
(L1 and L2 genes) that contains the genes that expresses the viral capsid proteins [8, 9]. 
Differential expression of HPV proteins during the viral cycle is important for virus replica-
tion and evasion of the host immune response. In new infected cells, the HPV replication starts 
with the expression of low levels of HPV E6 and E7 viral oncoproteins that generates cellular 
proliferation and genome instability [10, 11]. First, the major viral oncoprotein E7 binds to the 
retinoblastoma tumor suppressor protein (pRb), which allows the cell to continue into the cell 
cycle [12]. Simultaneously, the E6 oncoprotein is expressed, and binds to the cellular ubiquitin 
ligase E6AP, which in turn results in degradation of the p53 protein, a transcription factor 
for cell cycle arrest, and in extreme situations, for induction of apoptosis [12]. As the infected 
basal cells migrate to the upper layers and differentiate, viral DNA replication is favored by 
the binding of E1 and E2 proteins to the LCR to regulate viral proteins expression [13, 14]. 
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Once the viral DNA replication ends, the E2 protein represses the expression of the E6 and E7 
oncogenes to allow the continuation of the viral cycle [15]. In the middle of this process, the 
E5 oncoprotein is expressed to maintain for a longer time the S-phase of the cell cycle and to 
delay the differentiation process to allow the complete expression of the viral proteins and the 
viral DNA replication [16, 17]. In the upper layers, E4 protein interacts with the cytoskeleton 
collapsing the cytokeratin filaments and enhancing the liberation of viral particles [18, 19], 
and it is also involved in the viral DNA replication [20]. Finally, the two viral capsid proteins 
L1 and L2 are expressed in terminally differentiated cells, once the replication of the viral 
genome has been completed, and ending with the release of the viral particles [21–23].
On the other hand, during a HPV persistent infection, there is a gradual loss of regulation 
of the E6 and E7 expression genes, which allows the development of early cervical lesions 
(CIN 1–3; cervical intraepithelial neoplasia grade 1–3) [24]. However, more than 70% of the 
CIN lesions are eliminated by the immune system. Progression to CC occurs due to an over-
expression of E6/E7 oncoproteins, as a result of integration of the viral genome, which leads 
to the loss of the regulator E2 gene [15]. This is an important event in the carcinogenesis 
of CC, as the over-expression of E6 and E7 oncoproteins generates cellular immortalization 
[25], stop cellular differentiation that generates dysplasia, the cells became anergic for TNF-α 
(tumor necrosis factor) and TGF-β (transforming growth factor) [25, 26], and chromosomal 
rearrangements could occur, as has been observed with the c-myc gene [27].
During a normal viral cycle, all the early HPV proteins carry out their functions inside the 
cells, and the viral antigens are poorly exposed to the immune system of the host. However, 
persistence of HPV infection allows the production of antibodies. Although the antibodies 
generated against the early HPV proteins are not of neutralizing type, these are suitable for 
their study as possible biomarkers, which recently is under investigation.
3. Cancers associated with HPV infection
Among all human cancers, 15% are caused by viral infections. HPV infection is recognized as 
one of the major causes of infection-related cancers in both men and women. Generally, HPV 
has been associated with more than 90% of anal and cervical cancers, about 70% of vaginal 
and vulvar cancers, 70% of oropharyngeal cancers, and more than 60% of penile cancers [28].
The HPV is the most common sexually transmitted virus and the HR-HPV types 16 and 18 are 
more prevalent in CC (approximately 70%) [28]. This type of cancer has been a major public 
health problem among adult women in developing countries. The last worldwide report for 
CC identified more than 440,000 incident cases and over 230,000 deaths due to this disease [1]. 
HR-HPV infection is necessary but not sufficient to cause this cancer, which develops over a 
long period of time through precursor lesions at the squamocolumnar junction cells near the 
transformation zone [29]. These cells shown to be multipotent residual embryonic cells have 
also been identified at the anorectal junction similar to the cervix [29]. Although, the cellular 
origin and the HPV-DNA prevalence are similar in the anus and in the cervix, the incidence 
ratio of cervical/anal cancer is quite different (17:1) [30]. The majority of low-grade squamous 
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intraepithelial lesions (LSIL) do not progress to high-grade lesions (HSILs) or carcinoma, 
which suggests that the HPV infection alone is not sufficient to generate cancer, as other cofac-
tors such as immune deficiency, host genetic factors, among others are involved [30].
In anal cancer (AC), the HPV infection is detected in 80–90% of the cases, and HPV16 is 
the predominant type (80%) [31, 32] with a frequency higher than in other anatomical sites 
[32, 33]. This high frequency of HPV16 may reflect a differential tropism of this type that leads 
to malignant transformation in the anal mucosa. The prevalence of HPV in AC differs by 
geographic region, with the highest prevalence in North America and Europe and the lowest 
in Africa [31]. From the gastrointestinal tract malignancies, the prevalence of AC is around 
2–3%, with 27,000 new cases reported worldwide in 2008 [31].
Vulvar cancer (VC) is originated from a precursor in intraepithelial lesions named vulvar 
intraepithelial neoplasia (VIN) and this type of cancer accounts for >90% of the malignant 
tumors in the vulva [34]. Recently, there is increasing evidence that suggests two different 
etiopathogenic pathways for the development of VC, one that is associated to HR-HPV and 
the second that is HPV independent. The prevalence of HPV-DNA in VIN lesions varied 
from 52 to 100%, but it is over 90% in VC [32, 34]. Over the last decade, the incidence of HPV-
associated VC has increased mainly in young women, probably because of high-risk sexual 
behavior and a better recognition of these lesions due to HPV-DNA detection [32, 35].
On the other hand, penile cancer (PC) has been considered a relatively rare malignancy in 
the western world, although recent reports indicate an increase in incidence rates in develop-
ing countries (from 0.8 to 1.4/100,000) [36]. The etiology of PC is multifactorial with multiple 
established risk factors including infection with HPV. Epidemiological studies found that 48% 
of evaluated PC samples were positive for HPV-DNA and the type 16 or 18 was implicated 
in approximately 31% of these tumors, with HPV16 being the predominant type [37, 38]. In 
men, HPV infection can result in a spectrum of genitourinary manifestations that can cause 
genital warts, penile intraepithelial neoplasia (PIN), and PC. However, most HPV infections 
are asymptomatic, and up to 70% are cleared within 1 year [38].
The final group of the HPV-associated cancers is the one related to the head and neck cancer 
(HNC) that is the fifth most common cancer in the world [1]. Every year, there are more than 
640,000 cases of this cancer reported and it causes over 350,000 deaths [1]. Squamous cell carci-
noma is the most frequent type of neoplasia lesions affecting the head and neck area [39]. The 
laryngeal cancer (LC) is the most common among head and neck neoplasia and it accounts for 
about 60% of all cancers in the head and neck area [39]. LC may result from late complications 
of squamous cell papilloma (SCP), although most of those malignant changes develop with-
out papillomas. Generally, squamous laryngeal cancer development begins with dysplastic 
changes within the epithelium of mucosa membrane lining the organ, this is followed by an 
intraepithelial neoplasia and finally the development of the pre-invasive cancer (carcinoma in 
situ) [39, 40]. However, HPV involvement in LC etiology has not yet been fully evaluated [41].
Within this group of cancers, oropharyngeal carcinomas (OPC) are the most dependent on 
HPV. The incidence of HPV-positive OPC has been markedly increasing in North America 
and Europe, with a higher rate in men than in women in North America [30], and HPV16 
has been detected in the majority of these cancer cases [40]. Until now, little is known about 
the transmission and immunogenicity of HR-HPVs within the oropharynx. There is a strong 
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association with having performed oral sex and the number of lifetime partners [42], sug-
gesting that initial infection of HPV in the oropharynx is related to high-risk sexual activity. 
HPV nucleic acid examination in rinse and gargle samples showed a prevalence of 4.7% of 
HR-HPV infection in the general population among the ages 45–65 years old. However, it is 
still unclear the implications of the viral infection in the development of OPC [42].
Moreover, esophageal cancer (EC) is the leading cause of cancer mortality worldwide, with 
approximately 500,000 incident cases and more than 400,000 deaths each year [1]. There are 
two types of EC; the most common is the squamous cell carcinoma (ESCC), which is highly 
prevalent in Eastern countries and in developing countries. The second type is the adenocar-
cinoma (EAC), which is associated with Barrett’s esophagus, and its incidence has raised by 
5–10% each year, in developed (Western) countries [43].
4. Immune response to the HPV infection
Mucosal HPV infections frequently arise in the anogenital tract and in the head and neck 
region, and these sites of infection have high threshold of immune tolerance [44].
The infection and replication of HPV is restricted to differentiating epithelial cells, where 
there is a limiting presentation of viral antigens to the host immune system. As a result, there 
is a low but detectable humoral immune response in most infected individuals [45]. HR-HPV 
types 16 and 18 mainly induce persistent infections without frequent serious complications for 
the host; they are also highly successful in releasing viral particles transmissible to others [46]. 
This virus takes the host to a point of balance where the infection does not represent a serious 
drawback, and viral replication is not limited by the host immune response [46], because the 
virus does not have a blood-borne phase or viremia. The HPV infection does not induce necro-
sis, cytolysis, or inflammation, and as a result, there is little or no release of pro-inflammatory 
cytokines in the local environment [47]. The HPV viral cycle occurs in cells that are destined 
for death by anoikis (detachment), and because of this, there are no danger signals to alert the 
immune system to generate an efficient response to eliminate the infection [48].
It is well documented that more than 80% of the genital lesions caused by HPV infections are 
cleared as a result of a successful cell-mediated immune response, during which cells of the 
innate immune system such as keratinocytes, dendritic cells (DCs), Langerhans cells (LgCs), 
macrophages, natural killer (NK), and NKT cells, may play an important role in clearing the 
infection by promoting a pro-inflammatory process [49]. In the female genital track, the natu-
ral host of the HPV infection, there are keratinocytes that could act as immune sentinels, as 
it has been shown in skin [50]. These cells express Toll-like receptors (TLRs, belonging to 
the pathogen recognition receptors (PRR) family) on the cell surface (TLR-1, -2, -4, -5 and -6) 
and in the endosomes (TLR-3 and -9). Specifically, TLR-9 is activated by unmethylated dou-
ble-stranded CpG-rich DNA [51], allowing the secretion of interferons (IFNs) to activate the 
NK cells [52], which in turn kill the HPV-infected cells [53]. However, if the HPV infection 
becomes persistent, there is a downregulation of the innate immune response, which facili-
tates the virus to escape from the immune system. This mechanism could be through the 
downregulation of the IFN response by the oncoproteins E6 and E7 that interfere with differ-
ent molecules involved in the signal transduction pathways of these cytokines [54].
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Conversely, the LgCs and DCs (antigen-presenting cells) initiate the adaptive immune 
response to eliminate the HPV infection, through antigen-specific presentation to B and T 
cells in the lymph node. In this process, there is a generation of a Th1-type microenviron-
ment by secretion of pro-inflammatory cytokines, which helps to activate Tc cells (directed 
against the early HPV proteins E2, E6 and E7) to kill the infected cells [55]. This immuno-
logical response is complemented by the generation of neutralizing antibodies against the L1 
capsid protein to further inhibit the spread of the viral infection, but the virus uses several 
strategies to evade this adaptive immune response [56]. Recently, it was demonstrated that 
E2, E6, and E7 proteins upregulate the expression of IL-10 and TGF-β by interacting with 
their promoters, which allows an immunosuppressive environment [56]. Additionally, the 
E5 oncoprotein regulates the antigen presentation to the Tc cells by retaining the MHC-I in 
the Golgi apparatus, and preventing the MHC-I complex transportation to the cell membrane 
[57]. Besides, the antigen presentation to the Th cells is also regulated by E5, since this protein 
prevents the acidification of the endosomes, where the MHC-II restricted antigen is processed 
[58]. At the end, the immune system fails to clear the HPV infection as a result of an imbal-
ance between Th1 (pro-inflammatory) and Th2 (anti-inflammatory) cytokines, which allows a 
persistent infection with a high risk for the development of CC [56, 59].
Finally, the humoral immune response against the HPV infection is driven through the acti-
vation of the B-cell receptor by recognition of HPV antigens and stimulation by the CD40 Th 
cells receptor that allows the differentiation into plasma cells to produce antibodies against 
HPV proteins [48]. In this way, a differential antibody response against different HPV anti-
gens (E1, E2, E4, E5, E6, E7, L1, and L2) is generated and detected in the sera of HPV-infected 
women [60], and specifically, anti-E7 antibodies have been identified and associated to CC, 
and suggested as a possible markers for late stages of this disease [61–65].
5. Humoral immune response against human papillomavirus 
antigens
For several decades, the humoral immune response against HPV proteins has been used to 
study the viral cycle, and more recently as markers of HPV-associated cancers at different 
anatomical sites [66]. In this regard, some studies showed that seroconversion and the pres-
ence of anti-HPV antibodies were associated to the occurrence of precancerous lesions at dif-
ferent anogenital sites such as CC, AC, and from other sites like oral cancer (OC) [66, 67].
The presence of anti-HPV antibodies has been investigated through several epidemiological 
studies in several populations with different exposures to the virus and found a great variety 
in the prevalence and kinetics of these antibodies. The variations observed in the antibody 
response could depend on the population type, anatomical site of infection, viral antigens 
present, among others, but also the detection method may influence the antibody results 
observed (Tables 1 and 2). The immune response to the HPV proteome (or lack thereof) may 
provide some biological clues required to answer some of these questions. The HPV onco-
proteins E6 and E7 are early viral proteins that drive neoplastic transformation, are reliable 
indicators of an HPV-associated neoplasia, and can lead to detectable serum antibodies prior 
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to and at time of diagnosis, as well as post treatment [68]. To evaluate the serum antibod-
ies against HPV antigens, generated during infection, precancerous lesions and cancer, sev-
eral laboratory technics have been used, such as the ELISA (enzyme linked immunosorbent 
assay), western blot, radioimmunoassay (RIA) and more recently, Luminex multiplex. These 
methods use different antigens such as L1 virus like particles (VLPs) from different HPV 
types; synthetic peptides from L1, L2, E2, E4, and E7, bacterial recombinant proteins, or in 
vitro-translated viral antigens [7, 69].
A large number of epidemiological and clinical studies have been carried out to search for the 
presence of antibodies against HPV proteins and to identify associations of these serological 
markers with different types of anogenital cancers. In this sense, antibodies against proteins 
L1, E4, E6, and E7 from HPV16 are the most explored and are most frequently associated with 
different HPV-associated cancers (Table 1) [62, 66, 69–89].
Until now, the anti-L1 antibodies are more commonly associated to anal, penile, vulvar, vagi-
nal, and cervical cancer, but the results are contradictory. Some researchers found similar 
prevalence of anti-L1 antibodies in controls and in penile, vulvar, and vaginal cancer cases 
(17-38%) [66, 79], while others have shown higher prevalence of anti-L1 antibodies in AC 
(~54%) and CC (~68%) than in controls [79, 82]. These variations could be the result of differ-
ent sensitivities in the tests used, as well as the purity and the origin of the viral antigens [55, 
90]. Even though there are anti-L1 antibodies present in different types of cancer, these anti-
bodies do not differentiate the anatomical site of the HPV infection or the lesion site. Still some 
differences have been identified, as anti-E7 antibodies are good markers for CC and anti-E6 
antibodies for OC [62, 91]. In this way, several studies have been carried out and showed that 
antibodies against E7 have been commonly associated with AC and CC, with prevalence that 
goes from 45% in the anus [78] and up to 75% in the cervix [62, 69], while in the penis, vulva, 
and vagina, the antibody prevalence was under 15% [79]. In contrast, although serological 
antibodies against E6 prevalence were high in CC patients by using different tests (from 37 to 
44%) [70, 86], the association of anti-E6 antibodies with this type of cancer has not been very 
well defined [70, 74, 75, 88].
One of the most studied HPV proteins is E4, and this is probably due to its abundance 
(20–30% of total protein in condylomas) and to its differential production along the viral 
cycle [92]. During HPV DNA replication in low-grade lesions, high expression levels of 
E4 protein are observed, while in high-grade lesions, this protein is almost absent [24, 92, 
93]. As a result of these observations, the E4 protein is proposed as a marker of viral rep-
lication [92, 93]. However, the methodology to detect E4 protein relies on biopsy samples, 
which are difficult to obtain. For that reason, the detection of HPV antibodies has become 
a more sensitive system to indirectly follow-up the expression of viral proteins. Several 
epidemiological studies have shown higher prevalence of anti-E4 antibodies is observed 
in women with premalignant lesions than among CC cases or in the general population 
[62, 75, 94, 95]. Previously in our laboratory, we showed that anti-E4 antibodies were in low 
prevalence in healthy women (11%), but the prevalence increased in subjects with CIN1-3 
lesions (70%), and slightly decreased in CC (60%), which suggests an early recognition of 
this protein by the immune system [61, 62], and postulated as early markers of the disease 
(Table 1).
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In contrast, little is known about the presence of anti-E4 antibodies in other anogenital HPV-
associated cancers. The study of Kreimer and coworkers [79] carried out in AC, VC, and PC 
patients identified prevalence of anti-E4 antibodies under 30%, but they did not look for these 
Cancer type Method Population Serum antibodies (%) Ref.
E1 E2 E4 E6 E7 L1
Anal ELISA AC cases 70 45 50 [78]
ELISA Hospital controls and 
AC cases
25–52 [71, 72]
Multiplex GST Anogenital cancer cases 21 13 29 29 33 54 [79]
Penile ELISA VLPs Hospital controls and 
PC cases
63 [84]
ELISA L1 Hospital controls and 
PC cases
11 24–38 [66, 71, 72]
Multiplex GST Anogenital cancer cases 8 13 17 8 13 17 [79]
Vulvar ELISA VLPs Hospital controls and 
VC cases
27 [84]
ELISA L1 Hospital controls and 
VC cases
43 [72]
Multiplex GST Anogenital cancer cases 5 8 16 2 8 27 [79]
Vaginal ELISA VLPs Hospital controls and 
cancer cases
27 [84]
ELISA L1 Healthy controls and 
cancer cases
44 [72]
ELISA Hospital controls and 
cancer cases
0 26 [66]
Multiplex GST Anogenital cancer cases 0 0 0 8 0 25 [79]
Cervical 
cancer
Multiplex GST Healthy controls and 
CC
10 12 17 32–37 28–42 19–44 [70, 74, 75, 88]
Western blot Healthy controls and 
CC
60 75 [62]
ELISA Healthy controls and 
CC
19–54 13–53 28–68 [63, 70, 76, 77, 
81–83, 86, 87]
RIA Healthy controls and 
CC
50–51 33–39 56 [76, 80]
Luminex 
multiplex
Healthy controls and 
CC
11–44 14–61 21–35 [70, 73, 89]
Slot blot Healthy controls and 
CC
73 80 40 [69]
AC, anal cancer; PC, penile cancer; VC, vulvar cancer; CC, cervical cancer.
Table 1. Antibodies against HPV16 antigens in different types of anogenital cancers.
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antibodies in early lesions of these anogenital cancers, where this early HPV marker should 
be the prevalent, as it was observed for CC (Table 1).
Antibodies against E1 and E2 have been analyzed in anogenital cancers and only in AC, the 
anti-E2 antibodies have been observed with high prevalence (70%), which is through the use 
of peptides in ELISA [78]. However, a more recent study using a multiplex assay showed 
that the prevalence of these anti-E2 antibodies was fewer than 15% [79]. In the case of CC, 
the observed prevalence of anti-E1 and anti-E2 antibodies was under 15% [75] (Table 1), but 
the prevalence of anti-E2 in different degrees of cervical lesion by ELISA was high in CIN1-2 
lesions (64%), and it decreased with the increasing severity of the cervical lesion (CIN3, 31%) 
[96, 97]. Overall, these data suggest that anti-E2 antibodies could constitute a good biomarker 
for CIN lesions, but these need further studies.
Cancer type Method Population Serum antibodies (%) Ref.
E1 E2 E4 E6 E7 L1
Tongue ELISA Healthy controls 
and TC
25 4–21 [66, 84]
Oral cavity ELISA Hospital controls 
and OC
12–25 [84]







8 6 8 1 6–14 5–23 [101, 102]
Oropharyngeal ELISA GST Healthy controls 
and OPC
63–74 36–72 24–42 42–90 12–80 6–33 [66, 100, 
103–105]
Luminex GST Healthy controls 
OPC and Partners






16–21 24–25 11–13 30–35 20–25 14–42 [101, 102]
OPC and 
Non-OPC
37–70 45–77 34–45 61–85 47–72 55–61 [107, 108]
OPC 64 84 36 90 71 70 [91]







9 5 12 1–2 6–12 3–24 [101, 102]
Esophageal ELISA Hospital controls 
and EC cases






6 5 8 0.3–3 5–9 2–23 [101, 102]
TC, tongue cancer; OC, oral cancer; ADC, aero-digestive cancer; OPC, oropharyngeal cancer; LC, laryngeal cancer; EC, 
esophageal cancer.
Table 2. Antibodies against HPV16 antigens in different types of head and neck cancers.
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The presence of anti-E5 antibodies in cervical lesions has been described in only one report by 
using a microarray assay, but no associations were identified with any stage of the uterine cer-
vical lesions [98]. It is necessary to characterize better anti-E5 antibody response, with a more 
sensitive and specific assay, as this could be an interesting serological marker, since by look-
ing for the presence of E5 mRNA, this was associated with low-grade anogenital lesions [99].
Studies of anti-HPV antibodies in other HPV-associated cancers are underway, but the most 
recently studied are those localized in the head and neck sites, where different antibodies 
against E1, E2, E4, E5, E6, E7, and L1 viral proteins have been studied to try to identify associa-
tions with the presence of some type of cancer lesion in the oral cavity, in the tongue, pharynx, 
larynx, and even esophagus (Table 2) [66, 84, 91, 100–111].
The study of anti-HPV antibodies in sites such as the mouth and the esophagus began in the 
late 1990s, but more recently, the study of these antibodies has focused on lesions caused in 
the oropharyngeal area. In TC, low prevalence of anti-E7 antibodies (25%) and anti-VLPs 
(4–21%) antibodies were observed [66], while in OC, the prevalence of anti-E7 was under 
15%, but it was very variable for anti-VLPs antibodies (from 5 to 25%), differences that could 
depend on the methodology of antibody detection used (Table 2) [79, 84, 101].
One of the cancers in which the presence of anti-HPV antibodies has been analyzed in more 
detail is the OPC, in which ELISA and multiplex assays have been used with different HPV 
antigens. These studies strongly showed that anti-E6 antibodies are highly prevalent in OPC 
(from 30 to 85%), but this prevalence increased up to 90% when the OPC cases were HPV16 
positives [91, 102, 106]. However, this was not the case for anti-E7 antibodies, where the 
prevalence varied from 12 up to 80% [66, 103]. Also, some studies measured the antibod-
ies presence before and after cancer treatment, and they showed that seropositivity to E6 
and E7 significantly decreased after treatment. However, only anti-E6 antibodies showed an 
increased risk of disease recurrence, making these anti-E6 antibodies good biomarkers for 
disease prognostic [100, 103–105].
The other anti-HPV antibodies with high prevalence in OPC have been those against E1 
(~74%) and E2 (~77%) viral proteins [66, 100, 103–105, 107, 108], but this is not the case for 
other head and neck cancers, where the highest prevalence of antibodies against these viral 
antigens was under 10% (Table 2) [101]. Although the E4 protein is proposed as a marker of 
viral replication, in the case of OPC, the prevalence of anti-E4 antibodies was under 45%, and 
this was using the ELISA-GST system that is a highly sensitive method (Table 2) [104]. These 
studies suggest that the same serological markers are not present at the different anatomical 
site where the HPV-associated cancers appear. These results are very promising in the search 
for serological biomarkers, which in combination, they generate profiles that could differenti-
ate the anatomical sites where the HPV-associated cancer is present, as it has been the case 
for the profile anti-E1/E2 + anti-E6 that has been associated to OPC [91], and for CC, the sug-
gested antibody profile is anti-E4 + anti-E7 [69].
There are few studies that have analyzed anti-HPV antibodies in LC and showed low preva-
lence of the antibodies that varied from 2% for anti-E6 antibodies to a maximum of 24% for 
anti-L1 antibodies (Table 2) [66, 68, 101, 102]. Similar results have been reported for EC, and 
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the prevalence of anti-HPV antibodies fluctuated from 31% for anti-L1 antibodies and were 
under 10% for the rest of the anti-HPV antibodies [66, 68, 84, 109, 111]. At this moment, the 
identification of serological markers for LC and EC are inconclusive, and more studies need 
to be carried out with more sensitive methodologies such as the slot-blot system, but also a 
restriction to HPV positive cancer cases should be considered, as a low proportion of these 
two types of cancers are associated to HPV.
In addition, most of the studies of anti-HPV antibodies in different HPV-associated cancers 
have been carried out in the late stages of these cancers. It would be of great interest to study 
early stages of the HPV-associated cancers as some of these anti-HPV antibodies seem to be 
important in early diagnostic and during follow-up as possible prognostic markers. In the 
case of CC, there are several studies of anti-HPV antibodies carried out with precancerous 
uterine cervical lesions, where it has been suggested that anti-E4 antibodies are important 
markers for CIN1-2 [61, 62], while the profile anti-E4 + anti-E7 is a good marker for CC [69]. In 
the case of other HPV-associated cancers, there are only few studies that measured anti-HPV 
antibodies in early stages of the disease, as it is the case of anus and oral cavity lesions, where 
anti-VLPs antibodies presented the highest prevalence (43 and 30%, respectively) [111–115]. 
However, more studies are necessary to characterize the humoral immune response in the 
different HPV-associated cancers and their related precancerous lesions.
It is important to mention that differences in methodology and concerns about HPV misclas-
sification, aside from the heterogeneous responses in the antibody patterns seen in the vari-
ous studies, and in the different HPV-associated cancers require further evaluation. Besides, 
there are other confounding variables such as HPV type, viral load, viral exposure history, 
host immune system factors, and clinical risk factors. Therefore, prospective evaluations of 
anti-HPV serum antibodies should be controlled for as many of these factors. In addition, it 
is likely that an antibody signature consisting of a panel rather than a single antibody may 
provide the highest yield to be able to differentiate anatomical site, as well as early detection 
of these HPV-associated cancers.
6. Diagnostic and prognostic tests for HPV-associated cancers
Essentially all cervical cancers, most anal and oropharyngeal cancers, and some vaginal, vul-
var, and penile cancers are caused by HR-HPVs, but until now, there are no general guide-
lines for screening of all these HPV-associated cancers. Recently, the availability of new tests 
and ongoing research are changing the approach to screening and diagnosis of these types of 
cancers. However, most of the studies have been carried out in CC.
6.1. Cervical cancer
For CC, there are specific guidelines that have been modified in the last years, which include 
the introduction of new testing technologies, which have improved the early diagnostic of 
this disease. The cytology is the primary screening system for precancerous lesions and can 
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be done using Papanicolaou-stained smears (Pap), although this test has a low sensitivity 
(50–80%) [116, 117], and a high percentage of false positives, due to the fact that inflammatory 
cytology is considered abnormal [7, 117]. To confirm the presence of a uterine cervical lesion, 
a colposcopy test is required, which has a high sensitivity (80–95%) and a low specificity 
(23–63%), because the test becomes positive in the presence of an inflammatory process, and 
it is not useful to detect early uterine cervical lesions [118].
The introduction of molecular tests to detect DNA from HR-HPVs has shown to be highly 
sensitive and makes them good screening systems. Recently, there are different HPV molecu-
lar technics that are FDA (Food and Drug Administration, USA) approved to use in conjunc-
tion with cytology in CC screening programs. Among these tests are the Hybrid Capture® 2 
(HC2) (Qiagen, GmbH, Hilden Ger) and Cervista® HR-HPV Test (Hologic, Inc., MA, USA) 
that amplify the positive hybridization signal and allow the detection of multiple HR-HPV 
types in one step [119, 120]. The Cervista® HR-HPV and Cervista® HPV types 16/18 tests 
have shown to be complementary with a 100% of sensitivity for detection of CIN3+ and of 
98% for CIN2+ in women with diagnostic of ASC-US (atypical squamous of undetermined 
significance) by cytology and HR-HPV positive [121], system that has been approved by FDA.
On the other hand, HC2 has been tested at the general population for the detection of HPV 
worldwide. This system detects 13 HR-HPV types (-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, 
-58, -59, and -68) and 5 of low risk (LR) (-6, -11, -42, -43, and -44), and it is semi-quantitative 
(detects up to 1 pg HPV-DNA/ mL). The HC2 was FDA approved to detect women who have 
been referred to colposcopy with an ambiguous cytology of ASC-US and for the screening of 
women over 30 years old in conjunction with the cytology test [120]. Several epidemiological 
studies have shown the high predictive value of the HPV test for early detection of CC. This 
test is highly sensitive (93–98%) and specific (60–85%) to detect high-grade lesions, which 
makes the HC2 ideal for screening, and in combination with the cytology test increases the 
possibility to identified correctly women in risk to develop CC [3, 122, 123].
There are other systems to detect HPV-DNA by using reverse hybridization, some of which are 
INNO-LiPA® (Line Probe Assay, Innogenetics, Ghent, Belgium), CLART® HPV2 (Genómica, 
Madrid, Esp), Clinical Arrays® HPV (Genómica, Madrid, Esp) and the Linear Array® (Roche 
Mol Diagnostics, CA, USA), and this last one detects 37 HR- and LR-HPV types [119, 124]. 
The difference between these tests is the sensitivity as the LiPA detects from 10 to 100 DNA 
viral copies. These genotyping methods have a high sensitivity (95%) to detect CIN2+ lesions, 
making these tests suitable for screening the general population [119].
The detection of the HPV-DNA as indicator of the viral presence does not determine the pres-
ence of an active infection, and because of this, a complementary diagnostic test is necessary. 
Evaluation of viral load has been used as a biomarker of persistent infection, because cyto-
logical abnormalities are more frequently observed in CIN2-3 and CC with high viral load 
[125]. The viral load is determined by Real-time PCR and this system is highly sensitive and 
specific, and genotyping can be carried out in the same assay. Two diagnostic tests have been 
developed that use this technology, the Abbott Real-Time HR-HPV (Abbott Mol GmbH & Co. 
KG, Germany) and the COBAS® 4800 HPV (Roche Mol Diagnostics, CA, USA). These systems 
detect 14 HR-HPV types in one reaction, and use a colorimetric detection system to differentiate 
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the types 16 and 18; however, the sensitivity of COBAS® 4800 to detect CIN2 is higher (97%) 
than the one from Abbott (95%) [123, 126], and just recently have been FDA approved.
In the case of CC, the integration of HPV to the cellular genome seems to be an important 
part of the carcinogenesis, as this generates an abortive infection with high-level production 
of the E6 and E7 oncoproteins due to the loss of the E2 gene expression. This event causes 
the high expression of mRNA of the E6 and E7 oncogenes in the upper layer of the stratified 
epithelium in CIN2-3 and CC [127]. Thus, the E6/E7 mRNAs have been suggested as specific 
markers for precancerous lesions. In this way, several commercial tests have been developed 
to detect mRNAs from E6/E7 such as PreTect® HPV Proofer (NorChip AS, Norway) and 
APTIMA® HPV (Gen-Probe CA, USA). Both tests detect E6/E7 mRNAs by Real-time PCR, but 
PreTect® detects only 5 HPV types while APTIMA® detects 14 HR-HPVs, and this is carried 
on samples from liquid-based cytology. The APTIMA® assay has a similar sensitivity (98%), 
but higher specificity for HR-HPVs than HC2 (90% vs. 85%, respectively) to detect CIN2-3, 
making these molecules potential markers for the detection of high-grade lesions, but this is 
still under investigation [119, 128].
For more than 15 years, it was established that the treatment of early lesions (CIN1, ASC-US, 
and LSIL) was through follow-up patients with cytology and colposcopy for up to 2 years. 
However, this procedure is costly, and several visits to the medical office are required, and 
saturation of the colposcopy system, and loss of patients during the follow-up have made 
unable to give adequate treatment to those women at risk for developing CC. Because of these 
problems, it has been necessary to look for new biomarkers that allow the early identification 
of uterine cervical lesions that could progress to CC. From these efforts, some biomarkers 
have been identified and are described below.
The p16INK4a is an inhibitor of the cell cycle by inhibiting the hyperphosphorylation of pRb, 
through blocking the activity of the cyclin D-CDK4/6 complex. It has been observed that the 
inactivation of pRb by E7 results in the over-expression and accumulation of p16INK4a in the 
cells, making this protein a surrogated marker of E7 expression, which is associated to the CC 
development [129, 130]. The detection of p16INK4a is carried out in liquid-based cytology sam-
ples and in tissue biopsies by immunohistochemistry (IHC). Different epidemiological studies 
have demonstrated that p16INK4a is a good marker to identify HPV positive women with CIN 
2-3 [129, 130] and it is a useful marker to clarify 90% of ambiguous histopathological diagnos-
tics [131, 132]. The disadvantage of this biomarker is that in other non-associated HPV cancers 
also it is over-expressed [133].
The Ki-67 proliferation nuclear antigen (cell proliferation marker) is localized in the parabasal 
layer in the normal stratify uterine cervical epithelium, but during the development of CIN 
lesions, the expression of Ki-67 is extended all along the cervical epithelium. This marker 
is ideal to identify tumor cells, which correlates with the clinical stage of the lesion and the 
development of cancer. The detection of this Ki-67 marker is carried out in liquid-based 
cytology samples by IHC, and it is useful to detect CIN 2-3-associated HPV lesions [131]. 
Epidemiological studies in Europe and USA showed that Ki-67 can be used in combination 
with p16INK4a and helps to increase the sensitivity to a similar level as for HPV detection, but 
research is still under way to better characterize and validate these biomarkers [131, 132, 134].




The AC has similar features with CC, and natural history studies showed that high-grade 
anal intraepithelial neoplasia (AIN) is a precursor to invasive anal cancer. Because of these 
similarities, several features of the CC screening program have been taken for routine screen-
ing to detect precancerous anal lesions. In the general population, the Pap test to screening for 
precancerous anal lesions is carried out by taking a sample from the anal canal and the lesions 
are classified by using the Bethesda nomenclature. At the moment, anal cytology seems to be 
useful for screening of high-risk individuals, including HIV-positive patients [135].
In contrast, HPV testing has limited utility for AC screening because of the high prevalence 
of the infection and multiple HPV types in the anal canal of women and HIV-infected men. 
Only when the test is restricted to HPV16/18, the specificity of the test increased (77%), but the 
sensitivity dropped (62%), making this diagnostic system not suitable to detect individuals at 
risk to develop AC [136].
In AC, the high-resolution anoscopy is the standard procedure to diagnose this type of can-
cer, although several biomarkers such as Ki-67, p16INK4a, and others have been investigated to 
improve the accuracy of histologic diagnosis. Up to date, only the p16INK4a IHC test has been 
very well documented to increase the predictive positive value of the histopathology test to 
identify correctly AC cases [137].
In the case of other anogenital HPV-associated cancers such as vulvar, vaginal, or penile, the 
diagnostic is carried out by identifying a lesion by visual examination from the genital site to 
the perianal area, and confirming by performing a biopsy. Screening tests are not available 
and there are no recommended screening methods to detect HPV infections in these types of 
cancers. From the surrogated markers of HPV infection, p16INK4a was the only marker with 
sufficient data to support its utility in the evaluation of lower anogenital tract lesions [138].
6.3. Head and neck cancers
HNCs are often detected at late stages, as conventional visual and tactile examination is a way 
to diagnose this type of cancer. Substantial efforts to develop oral lesion detection systems 
such as those based on autofluorescence or tissue reflectance (e.g., the Dentlight Oral Exam 
Light kit, Microlux DL, Orascoptic DK, Sapphire Plus, Trimira Identafi 3000, and ViziLite-
Blue and VELscope) have been developed. However, the ability of these tests to discriminate 
between cancer and benign mucosal lesions is limited and because of this, the OC screening 
guidelines still do not recommend these diagnostic tests for routine screening of asymptom-
atic adults for HNCs [139]. The presence of HPV DNA in saliva was thought to be promising 
for early detection, but the test showed to have low sensitivity and specificity. For this reason, 
more studies are required to define the populations where the HPV test could have a positive 
impact and to evaluate the clinical value of this test [140].
On the other hand, the variable prevalence reported for HPV in HNCs could be attributed 
to the anatomical site where the sample is taken, but approximately 25% of all HNCs are 
HPV-DNA positive, and type 16 is the most prevalent. The variations in viral prevalence 
among different studies may be due to a combination of lesions of the different head and 
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neck anatomical subsites, sample sizes, sampling techniques (frozen, formalin-fixed or 
paraffin-embedded sections, scraping or oral rinses), and the methodologies used to detect 
HPV. Because of this, rigorous criteria should be considered for the separation of samples 
from the various anatomical subsites of the head and neck, as well as to increase sensitivity, 
specificity, accuracy, and reproducibility of the HPV tests for this type of cancer [140, 141].
Recently, it was suggested that HPV-DNA status in HNC should be analyzed together with 
other specific markers of active infection such as E6/E7 mRNAs transcription or p16INK4a 
expression, thus to better characterize these types of HPV-associated cancers. In this sense, 
the presence of E6/E7 mRNAs and p16INK4a expression was detected mostly in OPC [142]. 
Numerous other markers such as Ki-67, over-expression of epidermal growth factor receptor, 
p53, and others, have been studied in HNCs, but none of them have been consistently reliable 
[140, 141].
6.4. Serological biomarkers for the detection of HPV-associated cancers
The diagnostic of HPV infections for the detection of HPV-associated cancers has been dif-
ficult as there is no general screening test that alone or in combination with others allows the 
early identification of the disease. Because of this, it is necessary to look for tests that would 
be highly sensitive, specific, less invasive, and inexpensive, and that could be implemented at 
the general population.
It has been very well described that during the viral cycle, there is a sequential expression 
of the HPV proteins, which has been associated to different infection stages such as replica-
tion (associated to E4 protein), transformation (associated to E6/E7 proteins), and past infec-
tions (associated to L1 protein). Thus, the organism generates an antibody response against 
the viral antigens, in the same way as they are expressed during the viral cycle, letting the 
identification of different infection stages. Therefore, the humoral immune response natu-
rally amplified the reaction against HPV antigens so that this becomes a good source of new 
biomarkers to detect HPV-associated premalignant lesions at risk of developing cancer. As 
a result, the presence of antibodies against E4 protein has been related to viral replication, 
whereas anti-E7 antibodies are considered markers of a current HPV-associated malignancy 
[7, 63, 143]. In this context, the use of serological markers has been constantly studied to 
identify patients with different types of cancer associated with HPV. At present, most of the 
studies have focused mainly on CC and HNCs.
To study these HPV serological biomarkers, different techniques and reagents have been 
developed; as for instance, recombinant fusion proteins have been used as antigens in 
Western blot; synthetic peptides with important immunogenic epitopes for B cell are used 
in ELISA tests and modifications of this technique have been used to increase the specificity 
and sensitivity of the assay (Tables 1 and 2). Other systems developed to detect HPV anti-
bodies involve the in vitro protein transcription and translation, and this is used for radio-
immunoassays and also for a novel slot-blot system [7, 61, 62, 69, 143]. The use of these tests 
to measure anti-HPV antibodies in different populations have shown the utility of these as 
biological markers of different types of lesions not only at the uterine cervix, but also at other 
anatomical sites.
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In the uterine cervix, antibodies against HPV16 E6 and E7 were detected late during the 
development of CC with a new streptavidin-biotin capture ELISA, and were pointed as bad 
prognosis markers [81]. In a retrospective study, by using an ELISA-GST, the presence of anti-
E6 and anti-E7 IgG antibodies were identified between 0.5 and 5 years before CC diagnosis, 
suggesting the usefulness of these antibodies as disease predictors [144]. More recently, in 
a study conducted by Salazar-Piña and coworkers, by using a novel slot-blot system, they 
showed that anti-E4 + anti-E7 antibodies discriminate CC from CIN 2-3 lesions with high sen-
sitivity (80%) and a low false negative rate (20%), which corroborate the usefulness of these 
antibodies as markers for early detection of CC. In this study, they also observed that anti-E4 
antibodies alone could be useful as HPV exposure markers at early stages of the disease [69].
Similar results were also observed with OPC, where a bead-based multiplex serology method 
(multiplex-GST) was used to detect different anti-HPV antibodies and showed a strong asso-
ciation between HPV16 E6 seropositivity and the disease, which suggests that these antibod-
ies can be predictive markers of the disease as they were present more than 10 years before 
the cancer diagnosis [101, 102]. The sensitivity and specificity of this multiplex-GST system 
for anti-E6 antibodies was close to 100%, and because of that these antibodies have been pro-
posed as a tool for diagnosis and prognosis of HPV-OPC [91, 145]. This multiplex-GST sys-
tem also showed a high sensitivity (82%) and specificity (100%) for anti-E2 antibodies in the 
diagnosis of HPV-OPC. However, low sensitivity and specificity were observed for anti-E7, 
anti-E1, anti-E4, and anti-L1 antibodies [145].
All this together suggests that anti-HPV antibodies are promising diagnostic, prognostic, and 
potentially screening markers of HPV-associated cancers, as the presence of anti-HPV serum 
antibodies can vary according to the anatomical site where the cancer is generated by the 
HPV infection, however, more studies of anti-HPV antibodies are needed to validate them as 
serological markers for HPV-associated cancers.
7. Conclusions
This review of serological biomarkers is not intended to be an exhausted one, but rather to 
bring together the most important findings in the field and to point out the usefulness of 
these biomarkers in the diagnostic and prognostic of the different HPV-associated cancers. 
Numerous methods are being developed to detect HPV and related biomarkers that alone or 
in combination can be used to improve the positive predictive value of current screening meth-
ods, and to be able to identify precancerous lesions with a high risk of progression to cancer.
At present, serological anti-HPV antibodies are promising diagnostic, prognostic, and poten-
tially screening markers of HPV-associated cancers. It is likely that a combination of anti-HPV 
antibodies will generate profiles that could discriminate precancerous lesions in progression 
to cancer, and also to differentiate the presence of HPV-associated cancers at different ana-
tomical sites. For instance, it was shown that anti-E4 antibodies are associated to CIN1-2 
lesions and that the profile anti-E4 + anti-E7 antibodies are useful for early detection of CC, 
while the presence of anti-E1/E2 + anti-E6 antibodies are prognostic of OPC. Besides, the 
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immunoglobulin isotype also seems to play an important role in differentiating the site where 
the HPV infection develops, as it was shown in CC. It is clear that the presence of anti-HPV 
serum antibodies can vary according to the anatomical site where the cancer is generated by 
the HPV infection. These results are very promising, however, more studies with larger popu-
lations, different anatomical sites, evaluation in precancerous lesions, and the development 
of new and more sensitive methodologies are required to better characterize the humoral 
immune response against HPV and to validate these anti-HPV antibodies as serological mark-
ers of different HPV-associated cancers.
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